Immunotherapy Inside the Cell Interview by The Life Sciences Report
SAN FRANCISCO, CA--(Marketwired - January 08, 2016) - Targeting diseases from inside the cell could be medicine's version of the dawn of the Internet. Or, as newsletter writer Chen Lin describes it, advances from companies like Sorrento Therapeutics Inc. to introduce autologous immunotherapy intracellularly "opens a whole dimension." Dorman Followwill of Frost & Sullivan suggests this new approach could shift the focus from "therapy" to "cure," with rewards for the companies leading the way. In this article, The Life Sciences Report explores the possibilities of these new technologies -- and the prospects for companies like Sorrento, Inovio Pharmaceuticals Inc. and OncoSec Medical Inc. -- with Lin, Followwill and Ram Selvaraju of Rodman and Renshaw.
Think of a cancer cell as a castle surrounded by a moat. You can lay siege outside the walls, attack the walls themselves, or breach the walls and take out the command center. The first two modes of attack can be successful, but a comeback could be staged if defenses are rebuilt from inside. By taking out the core, everything crumbles. Better yet, nothing is left to stage a comeback with. Cancer cured.
To find out more about the promise of intracellular immunotherapies, both for patients and investors, The Life Sciences Report spoke with …
Continue reading this interview: Immunotherapy Inside the Cell: Three Companies on Their Way to the 'Holy Grail' of Cancer Treatment
About Streetwise Reports -- The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
Sorrento Therapeutics is a sponsor of Streetwise Reports. OncoSec Medical Inc. paid to distribute. Ram Selvaraju, Dorman Followwill and Chen Lin had final approval of the content and are wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Selvaraju, Mr. Followwill and Mr. Lin and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.